Cargando…
Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit
Background and Purpose: The European Association of Urology guidelines recommend restaging transurethral resection of bladder tumours (reTURB) 2–6 weeks after primary TURB. However, in clinical practice some patients undergo a second TURB procedure after Bacillus Calmette-Guérin immunotherapy (BCG)i...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602446/ https://www.ncbi.nlm.nih.gov/pubmed/33076249 http://dx.doi.org/10.3390/jcm9103306 |
_version_ | 1783603680707084288 |
---|---|
author | Krajewski, Wojciech Moschini, Marco Nowak, Łukasz Poletajew, Sławomir Tukiendorf, Andrzej Afferi, Luca Teoh, Jeremy Muilwijk, Tim Joniau, Steven Tafuri, Alessandro Antonelli, Alessandro Gozzo, Alessandra Mari, Andrea Di Trapani, Ettore Hendricksen, Kees Alvarez-Maestro, Mario Serrano, Andrea Rodriguez Simone, Giuseppe Zamboni, Stefania Simeone, Claudio Marconi, Maria Cristina Mastroianni, Riccardo Ploussard, Guillaume Rajwa, Paweł Laukhtina, Ekaterina Zdrojowy-Wełna, Aleksandra Kołodziej, Anna Paradysz, Andrzej Tully, Karl Krajewska, Joanna Piszczek, Radosław Xylinas, Evanguelos Zdrojowy, Romuald |
author_facet | Krajewski, Wojciech Moschini, Marco Nowak, Łukasz Poletajew, Sławomir Tukiendorf, Andrzej Afferi, Luca Teoh, Jeremy Muilwijk, Tim Joniau, Steven Tafuri, Alessandro Antonelli, Alessandro Gozzo, Alessandra Mari, Andrea Di Trapani, Ettore Hendricksen, Kees Alvarez-Maestro, Mario Serrano, Andrea Rodriguez Simone, Giuseppe Zamboni, Stefania Simeone, Claudio Marconi, Maria Cristina Mastroianni, Riccardo Ploussard, Guillaume Rajwa, Paweł Laukhtina, Ekaterina Zdrojowy-Wełna, Aleksandra Kołodziej, Anna Paradysz, Andrzej Tully, Karl Krajewska, Joanna Piszczek, Radosław Xylinas, Evanguelos Zdrojowy, Romuald |
author_sort | Krajewski, Wojciech |
collection | PubMed |
description | Background and Purpose: The European Association of Urology guidelines recommend restaging transurethral resection of bladder tumours (reTURB) 2–6 weeks after primary TURB. However, in clinical practice some patients undergo a second TURB procedure after Bacillus Calmette-Guérin immunotherapy (BCG)induction. To date, there are no studies comparing post-BCG reTURB with the classic pre-BCG approach. The aim of this study was to assess whether the performance of reTURB after BCG induction in T1HG bladder cancer is related to potential oncological benefits. Materials and Methods: Data from 645 patients with primary T1HG bladder cancer treated between 2001 and 2019 in 12 tertiary care centres were retrospectively reviewed. The study included patients who underwent reTURB before BCG induction (Pre-BCG group: 397 patients; 61.6%) and those who had reTURB performed after BCG induction (Post-BCG group: 248 patients, 38.4%). The decision to perform reTURB before or after BCG induction was according to the surgeon’s discretion, as well as a consideration of local proceedings and protocols. Due to variation in patients’ characteristics, both propensity-score-matched analysis (PSM) and inverse-probability weighting (IPW) were implemented. Results: The five-year recurrence-free survival (RFS) was 64.7% and 69.1% for the Pre- and Post-BCG groups, respectively, and progression-free survival (PFS) was 82.7% and 83.3% for the Pre- and Post-BCG groups, respectively (both: p > 0.05). Similarly, neither RFS nor PFS differed significantly for a five-year period or in the whole time of observation after the PSM and IPW matching methods were used. Conclusions: Our results suggest that there might be no difference in recurrence-free survival and progression-free survival rates, regardless of whether patients have reTURB performed before or after BCG induction. |
format | Online Article Text |
id | pubmed-7602446 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76024462020-11-01 Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit Krajewski, Wojciech Moschini, Marco Nowak, Łukasz Poletajew, Sławomir Tukiendorf, Andrzej Afferi, Luca Teoh, Jeremy Muilwijk, Tim Joniau, Steven Tafuri, Alessandro Antonelli, Alessandro Gozzo, Alessandra Mari, Andrea Di Trapani, Ettore Hendricksen, Kees Alvarez-Maestro, Mario Serrano, Andrea Rodriguez Simone, Giuseppe Zamboni, Stefania Simeone, Claudio Marconi, Maria Cristina Mastroianni, Riccardo Ploussard, Guillaume Rajwa, Paweł Laukhtina, Ekaterina Zdrojowy-Wełna, Aleksandra Kołodziej, Anna Paradysz, Andrzej Tully, Karl Krajewska, Joanna Piszczek, Radosław Xylinas, Evanguelos Zdrojowy, Romuald J Clin Med Article Background and Purpose: The European Association of Urology guidelines recommend restaging transurethral resection of bladder tumours (reTURB) 2–6 weeks after primary TURB. However, in clinical practice some patients undergo a second TURB procedure after Bacillus Calmette-Guérin immunotherapy (BCG)induction. To date, there are no studies comparing post-BCG reTURB with the classic pre-BCG approach. The aim of this study was to assess whether the performance of reTURB after BCG induction in T1HG bladder cancer is related to potential oncological benefits. Materials and Methods: Data from 645 patients with primary T1HG bladder cancer treated between 2001 and 2019 in 12 tertiary care centres were retrospectively reviewed. The study included patients who underwent reTURB before BCG induction (Pre-BCG group: 397 patients; 61.6%) and those who had reTURB performed after BCG induction (Post-BCG group: 248 patients, 38.4%). The decision to perform reTURB before or after BCG induction was according to the surgeon’s discretion, as well as a consideration of local proceedings and protocols. Due to variation in patients’ characteristics, both propensity-score-matched analysis (PSM) and inverse-probability weighting (IPW) were implemented. Results: The five-year recurrence-free survival (RFS) was 64.7% and 69.1% for the Pre- and Post-BCG groups, respectively, and progression-free survival (PFS) was 82.7% and 83.3% for the Pre- and Post-BCG groups, respectively (both: p > 0.05). Similarly, neither RFS nor PFS differed significantly for a five-year period or in the whole time of observation after the PSM and IPW matching methods were used. Conclusions: Our results suggest that there might be no difference in recurrence-free survival and progression-free survival rates, regardless of whether patients have reTURB performed before or after BCG induction. MDPI 2020-10-15 /pmc/articles/PMC7602446/ /pubmed/33076249 http://dx.doi.org/10.3390/jcm9103306 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Krajewski, Wojciech Moschini, Marco Nowak, Łukasz Poletajew, Sławomir Tukiendorf, Andrzej Afferi, Luca Teoh, Jeremy Muilwijk, Tim Joniau, Steven Tafuri, Alessandro Antonelli, Alessandro Gozzo, Alessandra Mari, Andrea Di Trapani, Ettore Hendricksen, Kees Alvarez-Maestro, Mario Serrano, Andrea Rodriguez Simone, Giuseppe Zamboni, Stefania Simeone, Claudio Marconi, Maria Cristina Mastroianni, Riccardo Ploussard, Guillaume Rajwa, Paweł Laukhtina, Ekaterina Zdrojowy-Wełna, Aleksandra Kołodziej, Anna Paradysz, Andrzej Tully, Karl Krajewska, Joanna Piszczek, Radosław Xylinas, Evanguelos Zdrojowy, Romuald Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit |
title | Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit |
title_full | Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit |
title_fullStr | Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit |
title_full_unstemmed | Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit |
title_short | Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit |
title_sort | restaging transurethral resection of bladder tumours after bcg immunotherapy induction in patients with t1 non-muscle-invasive bladder cancer might not be associated with oncologic benefit |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602446/ https://www.ncbi.nlm.nih.gov/pubmed/33076249 http://dx.doi.org/10.3390/jcm9103306 |
work_keys_str_mv | AT krajewskiwojciech restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT moschinimarco restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT nowakłukasz restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT poletajewsławomir restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT tukiendorfandrzej restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT afferiluca restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT teohjeremy restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT muilwijktim restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT joniausteven restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT tafurialessandro restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT antonellialessandro restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT gozzoalessandra restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT mariandrea restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT ditrapaniettore restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT hendricksenkees restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT alvarezmaestromario restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT serranoandrearodriguez restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT simonegiuseppe restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT zambonistefania restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT simeoneclaudio restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT marconimariacristina restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT mastroianniriccardo restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT ploussardguillaume restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT rajwapaweł restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT laukhtinaekaterina restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT zdrojowywełnaaleksandra restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT kołodziejanna restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT paradyszandrzej restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT tullykarl restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT krajewskajoanna restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT piszczekradosław restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT xylinasevanguelos restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit AT zdrojowyromuald restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit |